HSPG2 and posterior cortical atrophy: All these results, together with the fact that the HSPG2*Q1062H point mutation was predicted to be benign and the mutant peptide was downregulated in PCa patients, suggest that this mutant peptide may have beneficial effects in patients with PCa and opens doors for its study in PCa treatment.